288 related articles for article (PubMed ID: 22785335)
1. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
Rajendran R; Grossman AB; Kar P
Endocr J; 2012; 59(10):903-9. PubMed ID: 22785335
[TBL] [Abstract][Full Text] [Related]
2. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
[TBL] [Abstract][Full Text] [Related]
3. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
Humayun MA; Cranston IC
BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
[TBL] [Abstract][Full Text] [Related]
4. Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
Pose-Reino A; Runkle de la Vega I; de Jong-Laird A; Kabra M; Lindner U
Adv Ther; 2021 Feb; 38(2):1055-1067. PubMed ID: 33306187
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
6. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of hyponatraemia in the older patient.
Woodward M; Gonski P; Grossmann M; Obeid J; Scholes R; Topliss DJ
Intern Med J; 2018 Jan; 48 Suppl 1():5-12. PubMed ID: 29318728
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
[TBL] [Abstract][Full Text] [Related]
10. Tolvaptan and urea in paediatric hyponatraemia.
Veligratli F; Alexandrou D; Shah S; Amin R; Dattani M; Gan HW; Famuboni A; Lopez-Garcia C; Trompeter R; Bockenhauer D
Pediatr Nephrol; 2024 Jan; 39(1):177-183. PubMed ID: 37466863
[TBL] [Abstract][Full Text] [Related]
11. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
Estilo A; McCormick L; Rahman M
Adv Ther; 2021 Dec; 38(12):5721-5736. PubMed ID: 34693505
[TBL] [Abstract][Full Text] [Related]
12. Tolvaptan.
Plosker GL
Drugs; 2010 Mar; 70(4):443-54. PubMed ID: 20205486
[TBL] [Abstract][Full Text] [Related]
13. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial.
Warren AM; Grossmann M; Hoermann R; Zajac JD; Russell N
Trials; 2022 Apr; 23(1):335. PubMed ID: 35449020
[TBL] [Abstract][Full Text] [Related]
15. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
16. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
17. Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care.
Tzoulis P; Carr H; Bagkeris E; Bouloux PM
Endocrine; 2017 Feb; 55(2):539-546. PubMed ID: 27837439
[TBL] [Abstract][Full Text] [Related]
18. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
Marx-Berger D; Milford DV; Bandhakavi M; Van't Hoff W; Kleta R; Dattani M; Bockenhauer D
Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
[TBL] [Abstract][Full Text] [Related]
19. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
20. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.
Petereit C; Zaba O; Teber I; Lüders H; Grohé C
BMC Pulm Med; 2013 Aug; 13():55. PubMed ID: 23987478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
